LATE-BREAKING ABSTRACT: Pulmonary deposition of a novel LAMA/LABA Co-Suspension™ technology glycopyrronium/formoterol (GFF) MDI in healthy subjects (PT003020)
Glyn Taylor, Simon Warren, Chad Orevillo, Andrea Maes, Ubaldo J. Martin, Sarvajna Dwivedi, Colin Reisner
European Respiratory Journal 2016 48: OA4834; DOI: 10.1183/13993003.congress-2016.OA4834
Glyn Taylor
1Cardiff Medicentre, Cardiff Scintigraphics, Cardiff, United Kingdom
Simon Warren
1Cardiff Medicentre, Cardiff Scintigraphics, Cardiff, United Kingdom
Chad Orevillo
2Global Medical Affairs, Pearl Therapeutics, Inc., Morristown, NJUnited States
Andrea Maes
2Global Medical Affairs, Pearl Therapeutics, Inc., Morristown, NJUnited States
Ubaldo J. Martin
3Research and Development, Clinical Development, AstraZeneca, Gaithersberg, MDUnited States
Sarvajna Dwivedi
4Product Development, Pearl Therapeutics, Inc., Redwood City, CAUnited States
Colin Reisner
2Global Medical Affairs, Pearl Therapeutics, Inc., Morristown, NJUnited States
Vol 48 Issue suppl 60
Table of Contents
LATE-BREAKING ABSTRACT: Pulmonary deposition of a novel LAMA/LABA Co-Suspension™ technology glycopyrronium/formoterol (GFF) MDI in healthy subjects (PT003020)
Glyn Taylor, Simon Warren, Chad Orevillo, Andrea Maes, Ubaldo J. Martin, Sarvajna Dwivedi, Colin Reisner
European Respiratory Journal Sep 2016, 48 (suppl 60) OA4834; DOI: 10.1183/13993003.congress-2016.OA4834
LATE-BREAKING ABSTRACT: Pulmonary deposition of a novel LAMA/LABA Co-Suspension™ technology glycopyrronium/formoterol (GFF) MDI in healthy subjects (PT003020)
Glyn Taylor, Simon Warren, Chad Orevillo, Andrea Maes, Ubaldo J. Martin, Sarvajna Dwivedi, Colin Reisner
European Respiratory Journal Sep 2016, 48 (suppl 60) OA4834; DOI: 10.1183/13993003.congress-2016.OA4834